<DOC>
	<DOCNO>NCT01765608</DOCNO>
	<brief_summary>This RCT explore efficacy Zonisamide ( Zonegran® ) overweight/obese patient moderate severe obstructive sleep apnea . Patients randomize receive zonisamide , placebo nasal continuous positive airway pressure ( nCPAP ) 4 week . A 5 month open extension part follow patient tablet group receive zonisamide . Patients open CPAP group continue CPAP treatment . Study hypothesis : Controlled pharmacological weight reduction Zonisamide result elimination OSA OSA sequel effectively nCPAP due incomplete compliance mechanical treatment lack direct beneficial metabolic effect nCPAP . Further hypothesize zonisamide direct pharmacological effect respiratory control sleep carbonic anhydrase inhibitory effect result reduction sleep disorder breathing .</brief_summary>
	<brief_title>Zonisamide Treatment Obstructive Sleep Apnea Overweight/Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Males/females 18 75 year An ApneaHypopnea Index ( AHI ) &gt; 15 Epworth Sleepiness Scale score ( ESS ) &gt; 6 Body mass index ( BMI ) &gt; 27 &lt; 35 kg/m2 ( mild moderate ) Clinically normal physical finding laboratory value , judge investigator Hypersensitivity sulfonamides zonisamide . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity Subjects seizure disorder Clinically significant renal ( serum creatinine &gt; 2.0 mg/dL &gt; 130 µmol/L ) , neurological , metabolic ( e.g . Type 1 2 diabetes ) , haematological hepatic disease ( ASAT ALAT &gt; 2 time upper limit normal ) . Subjects take weight loss medication ( prescription overthecounter ) within one month prior Enrollment Subjects occupation designate high risk safety sensitive include patient handle complex machinery professional driver may increase risk work traffic accident . Unstable angina pectoris Unstable hypertension ( diastolic blood pressure 100 treatment 3 month ) , diabetes ( fast plasma glucose 7 mmoles/l ) Uncontrolled congestive heart failure Myocardial infarction coronary vessel intervention within previous 6 month period Subjects uncontrolled hypertension ( define diastolic blood pressure ≥100 mmHg and/or systolic blood pressure ≥180 mmHg without medication ) . Hypertensive subject medication must dose antihypertensive medication least two month prior Enrollment . Previously diagnose treat clinically significant cardiac arrhythmia Clinically significant chronic pulmonary gastrointestinal disease Clinical history depression judge investigator previous present clinically significant psychiatric disease Pregnancy lactation . Women childbearing potential use effective birth control prior study Suspected confirm poor compliance Alcohol drug abuse last year Subjects significant condition , opinion investigator , could interfere participation study . Severe nocturnal hypoxia define 10 episode oxygen desaturation exceed 50 % sign lack resaturation desaturations previous recording accord investigator judgement . Participation another clinical study last 6 month Inability understand complete questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Zonisamide</keyword>
	<keyword>Zonegran</keyword>
	<keyword>Obstructive Sleep apnea</keyword>
	<keyword>Apnea</keyword>
	<keyword>Respiration Disorders</keyword>
	<keyword>Sleep Disorders</keyword>
	<keyword>Obesity</keyword>
	<keyword>Anti-Obesity Agents</keyword>
	<keyword>Carbonic Anhydrase</keyword>
	<keyword>Carbonic Anhydrase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Sulfonamides</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>